Buy License
Investor relations
Log-in for recent financial and business updates.
At CLC bio we prefer our network of investors to grow along with the growth in our customer-base and sales volume. If you are interested in joining the exclusive club of CLC bio shareholders, send an e-mail to CEO and IR manager Thomas Knudsen for additional information.Business area
CLC bio is the world's leading bioinformatics solution provider. Our primary business focus is to provide fast, advanced, and user-friendly IT solutions for extracting scientific value from the massive amounts of DNA and RNA data that are generated by the rapidly increasing fleet of Next Generation Sequencing instruments.CLC bio delivers the market’s first and only comprehensive IT solution for analyzing and visualizing genomic, transcriptomic, and epigenomic data from all Next Generation Sequencing platforms.
Our customers range from individual scientists buying advanced desktop based software for improving their academic or industrial research to research organizations purchasing comprehensive enterprise solutions for optimizing work processes and sustaining their scientific competitive edge in an ever changing scientific environment.
Company profile
At our headquarters in Denmark and at our offices in USA, India, UK, Brazil, and Singapore, we employ 41 world class experts in computer science and biology. Our sales partner network includes more than 20 partners in Asia, Oceania, Europe, Africa, and North America.CLC bio is owned by private, mainly Denmark and US-based, investors. Corporate governance, shareholder value, and visionary strategic planning are among our key management guidelines.
Our strategic positioning as the premier solution provider in the high-growth market of Next Generation Sequencing data analysis has led to continuous growth in all geographical regions and within all major product-lines. Our year-on-year sales volume has continuously doubled throughout the last 4 years.
